Hi all! I know this would be a long shot but I've recently been tasked to do a Biotech M&A Info Memo (Public Company, thus inclusive of EPS Accretion/Dilution analysis) in America. Would have anyone have some templates?
Currently, I'm working in a general boutique and this is our 1st biotech deal unfortunately.
Thank you! :)
| +330 | Which Offer to Accept: UBS Analyst Role or Part Time Cashier at the Local Taco Bell | 42 | 15m |
| +276 | Roku-Fox Deal - UBS Misses Out on yet another deals after years chasing this deal | 26 | 46m |
| +262 | AI is insane | 33 | 1h |
| +243 | I Snuck Into UBS Office And Took A Shit On The Floor | 23 | 39m |
| +200 | Useless associates | 34 | 49m |
| +181 | Differences in Restructuring Teams? | 32 | 46m |
| +174 | How do you manage nerves in IB technical interviews? | 16 | 10h |
| +154 | TPH V.S. Mizuho [HOU] | 24 | 47m |
| +149 | GF is an IB Analyst at a top BB, hates it, what exit options does she have? | 26 | 13h |
| +148 | Shame on you Evercore - SA 28 | 39 | 1h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
If it helps, the company has two drugs. One in Clinical Phase III and another in Phase I.
My $0.02 but don't waste your energy and time on the Phase I compound because statistically speaking, the probability of it hitting the market is extremely low at this stage
Agreed. Also just super distant and not a realistic driver of value. Should be viewed more as an upside item but not as a core factor.
Eligendi facere illo et nulla nam praesentium est. Praesentium error distinctio necessitatibus quia nihil fugit. Quisquam rerum sunt necessitatibus voluptate minus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...